RECOMBINANT ANTIBODIES FOR IMMUNOTHERAPY

Abstract

Part I. Introduction: 1. Past, present and future of recombinant antibodies G. Winter Part II. Generation and Screening of Antibody Libraries: 2. Antibody libraries from naive V gene sources G. Beste and D. Lowe 3. Antibodies from IgM libraries V. Molkenthin and S. Knackmuss Part III. Transgenic Human Antibody Repertoires: 4. The generation and screening of synthetic antibody libraries I. Klagge 5. Therapeutic antibodies from xenoMouse transgenic mice A. Jakobovits 6. Transgenic chimeric antibodies A. Murphy Part IV. Humanised Antibodies: 7. Humanization of recombinant antibodies J. Saldanha 8. Immunogenicity assessment of antibody therapeutics P. Stas, J. Pletinckx, Y. Gansemans, and I. Lasters 9. In vitro screening for antibody immunogenicity F. Carr and M. Baker Part V. Antibody Effector Function: 10. Mechanisms of tumour cell killing by therapeutic antibodies R. Stewart and C. Webster 11. Optimization of Fc domains to enhance antibody therapeutics G. Lazar and A. Chamberlain 12. Glycoengineered therapeutic antibodies P. Brunker, P. Sondermann, and P. Umana Part VI. Arming Antibodies: 13. Monoclonal antibodies for the delivery of cytotoxic drugs D. King 14. Immunotherapy with radioimmune conjugates C. Kousparou and A. Epenetos 15. Immunotherapeutic antibody fusion proteins N. Courtenay-Luck and D. Jones Part VII. Antibody Fragments: 16. Alternative antibody formats F. Le Gall and M. Little 17. Single domain antibodies S. Muyldermans 18. Engineering of non-CDR loops in immunoglobulin domains F. Ruker and G. Wozniak-Knopp Part VIII. Antigen Binding Repertoires of Non-Immunoglobulin Proteins: 19. Alternative antibody scaffolds A. Plueckthun Part IX. Prolongation of Serum Half Life: 20. Polymer fusions to increase antibody half lives: PEGylation and other modifications S. Heywood and D. Humphreys 21. Extending antibody half-lives with albumin J. Andersen and I. Sandlie Part X. Current Therapeutic Antibodies and Novel Developments: 22. A stem cell-based platform for the discovery and development of anti-tumor therapeutic antibodies to novel targets J. Mather, C. Fieger, T. Liang, K. King, J. Li, P. Young, C. Beltejar, B. Potts, M. Licea, and D. Loo 23. Antibody directed enzyme prodrug therapy (ADEPT) H. Lowe, S. Sharma, and K. Bagshawe 24. Immune privilege and tolerance - therapeutic antibody approaches D. Forman, P. Ponath, D. Mehta, J. Ponte, J. Snyder, P. Rao, H. Waldmann, and M. Rosenzweig Part XI. Market Overview and Outlook: 25. Antibody therapeutics: business achievements and business outlook C. Bourrilly.